Yabao Pharmaceutical (600351.SH) terminates clinical research and development work on SY-009.

The Zhitong Financial APP announced that Yabao Pharmaceutical (600351.SH) has recently conducted a careful evaluation of the SY-009 research and development project. Taking into account factors such as the progress of the project, the risks involved in continuing development, and the future market value, in order to reasonably allocate the company's research and development resources and focus on the advantageous projects in the research pipeline, the company has decided to terminate clinical research and development work on SY-009. At the same time, in accordance with the "Enterprise Accounting Standards" and other relevant regulations, based on the principle of accounting prudence, the full amount of the research and development capitalization for this project will be provisioned for asset impairment.